Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec 12;272(1):46.
doi: 10.1007/s00415-024-12816-0.

Diagnosing primary lateral sclerosis: a clinico-pathological study

Eva M J de Boer  1 , Bálint S de Vries  1 , Wim Van Hecke  2 , Angelika Mühlebner  2 , Koen L Vincken  3 , Christian P Mol  3 , Wouter van Rheenen  1 , Henk-Jan Westeneng  1 , Jan H Veldink  1 , Günter U Höglinger  4   5   6 , Huw R Morris  7 , Irene Litvan  8 , Joost Raaphorst  9 , Nicola Ticozzi  10 , Philippe Corcia  11 , Wim Vandenberghe  12 , Yolande A L Pijnenburg  13 , Harro Seelaar  14 , Caroline Ingre  15 , Philip Van Damme  12   16 , Leonard H van den Berg  1 , Bart P C van de Warrenburg  17 , Michael A van Es  18
Affiliations
Case Reports

Diagnosing primary lateral sclerosis: a clinico-pathological study

Eva M J de Boer et al. J Neurol. .

Abstract

Background: Primary lateral sclerosis (PLS) is a rare motor neuron disease characterized by upper motor neuron degeneration, diagnosed clinically due to the absence of a (neuropathological) gold standard. Post-mortem studies, particularly TDP-43 pathology analysis, are limited.

Methods: This study reports on 5 cases in which the diagnostic criteria for PLS were met, but in which neuropathology findings showed (partially) conflicting results. These discrepancies prompted us to perform a clinico-pathology study focussing on diagnostic challenges and accuracy in PLS. To this end, all cases were reviewed by an international panel of 11 experts using an e-module and structured questionnaires.

Results: Autopsy exhibited neuropathological findings consistent with amyotrophic lateral sclerosis (ALS) in one case, while two cases exhibited similar, but more limited lower motor neuron involvement, hinting at PLS or ALS overlap. Another case displayed tau-pathology indicative of progressive supranuclear palsy. The final case displayed extensive myelin loss without a proteinopathy or a clear diagnosis. The expert panel identified 24 different ancillary investigations lacking across cases (e.g. genetic testing, DAT scans, neuropsychological evaluation), listed 28 differential diagnoses, and identified 13 different conditions as the most likely diagnosis. Autopsy results led panel members to change their final diagnosis in 42% of the cases.

Conclusions: This study underscores the diagnostic challenges posed by diverse underlying pathologies resulting in upper motor neuron phenotypes. Despite adhering to the same diagnostic criteria, consensus amongst experts was limited. Ensuring the diagnostic consistency is crucial for advancing understanding and treatment of PLS. Explicit guidelines for excluding potential mimics along with a neuropathological gold standard are imperative.

Keywords: Amyotrophic lateral sclerosis; Neuropathology; Primary lateral sclerosis; TDP-43; Tau.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: E.M.J. de Boer: reports no disclosures relevant to the manuscript. B.S. de Vries: reports no disclosures relevant to the manuscript. W. van Hecke: reports no disclosures relevant to the manuscript. A. Mühlebner: reports no disclosures relevant to the manuscript. K.L. Vincken: reports no disclosures relevant to the manuscript. C.P. Mol: reports no disclosures relevant to the manuscript. W. van Rheenen: reports no disclosures relevant to the manuscript. H-J Westeneng: reports no disclosures relevant to the manuscript. J.H. Veldink: reports to have sponsored research agreements with Biogen and Astra Zeneca. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement n° 772376 – EScORIAL. G.U. Höglinger: reports no disclosures relevant to the manuscript. H.R. Morris: reports no disclosures relevant to the manuscript. I. Litvan: reports no disclosures relevant to the manuscript. J. Raaphorst: reports no disclosures relevant to the manuscript. N. Ticozzi: reports no disclosures relevant to the manuscript. P. Corcia: reports no disclosures relevant to the manuscript. W. Vandenberghe: reports no disclosures relevant to the manuscript. Y.A.L. Pijnenburg: reports no disclosures relevant to the manuscript. H. Seelaar: reports no disclosures relevant to the manuscript. C. Ingre: reports no disclosures relevant to the manuscript. P. Van Damme: reports no disclosures relevant to the manuscript. L.H. van den Berg: declares fees to his institution from Biogen, Wave, Amylyx, Ferrer, and Cytokinetics for being on a scientific advisory board; fees to his institution from Amylyx for a lecture; an unrestricted educational grant from Takeda; and is the Chair of ENCALS and TRICALS. B.P.C. van de Warrenburg: reports no disclosures relevant to the manuscript. M.A. van Es: has consulted for Biogen, and has received travel grants from Shire (formerly Baxalta), performed work as a medical monitor for Ferrer (NCT05178810) with fees going to his institution. MAvE receives funding support from the Netherlands Organization for Health Research and Development (Vidi scheme), The Thierry Latran Foundation, the Motor Neurone Disease Association, FIGHT-MND and the ALS Foundation Netherlands. He is also a member of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD).

References

    1. Turner MR, Talbot K (2020) Primary lateral sclerosis: diagnosis and management. Pract Neurol 20(4):262–269. https://doi.org/10.1136/practneurol-2019-002300 - DOI - PubMed
    1. Jaiser SR, Mitra D, Williams TL, Baker MR (2019) Mills’ syndrome revisited. J Neurol 266(3):667–679. https://doi.org/10.1007/s00415-019-09186-3 - DOI - PubMed - PMC
    1. Ravits J, Appel S, Baloh RH et al (2013) Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 14(SUPPL1):5–18. https://doi.org/10.3109/21678421.2013.778548 - DOI - PubMed - PMC
    1. Turner MR, Barohn RJ, Corcia P et al (2020) Primary lateral sclerosis: Consensus diagnostic criteria. J Neurol Neurosurg Psychiatry 91(4):373–377. https://doi.org/10.1136/jnnp-2019-322541 - DOI - PubMed
    1. Mackenzie IRA (2020) Neuropathology of primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 21(sup1):47–51. https://doi.org/10.1080/21678421.2020.1837173 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources